The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.

Related News Articles

Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…
Headline
The AHA has extended the deadline to May 31 for organizations to submit applications for its 2019 Innovation Challenge.
Headline
Reps. Bradley Schneider, D-Ill., Don Bacon, R-Neb., and Abby Finkenauer, D-Iowa, yesterday introduced a House companion to AHA-supported legislation that would…
Insights and Analysis
Hospital and health system leaders shared how they are driving innovation to advance health and the patient experience at this week’s 20th Annual Not-for-…
Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…